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 2 
A BST R A C T 1 
One of the major goals of antidepressant treatment is a sustained response and remission 2 
of depressive symptoms. Some of the previous studies of vagus nerve stimulation (VNS) 3 
have suggested antidepressant effects. Our naturalistic study assessed the efficacy and 4 
safety of VNS in 74 European patients with therapy-resistant major depressive disorder. 5 
Psychometric measures were obtained after 3, 12, and 24 months of VNS. Mixed model 6 
repeated measures ANOVA revealed a sign(B()*'>"%$LA)>(&'"MNOP:PQR"*>"*44"S">(7$"N&('>="7 
in the Hamilton Rating Scale for Depression (HRSD28), the primary outcome measure. 8 
After 2 years, 53.1% (26/49) N*>($'>="BA4B(44$L"%$=N&'=$")%(>$%(*"MTQPU"%$LA)>(&'"('"9 
HRSD28 scores from baseline) and 38.9% (19/49) fulfilled remission criteria (HRSD28 10 
=)&%$="OVPR:"WI$"N%&N&%>(&'"&B"N*>($'>="XI&"BA4B(44$L"%$7(==(&'")%(>$%(*"%$7*('$L")&'=>*'>"11 
as the duration of VNS treatment increased. Voice alteration, cough, and pain were the 12 
most frequently reported adverse effects. Two patients committed suicide during the 13 
study; no other deaths were reported. No statistically significant differences were seen in 14 
the number of concomitant antidepressant medications. The results of this 2-year open-15 
label trial suggest a clinical response and a comparatively benign adverse effect profile 16 
among patients with treatment-resistant depression. 17 
 18 
K ey words: clinical trial; Hamilton Rating Scale for Depression; major depressive 19 
disorder; depression, vagus nerve stimulation  20 
IN T R O DU C T I O N  1 
The necessity for comparably safe, effective, and well tolerated, long-term 2 
treatments for chronic and treatment-resistant depression is well recognized. Although a 3 
broad range of effective treatments is available, a considerable proportion of patients do 4 
not respond adequately [1]. Patients who have experienced recurrent depressive episodes 5 
often relapse and do not achieve full remission despite treatment with conventional 6 
therapies [2-!"#$%&'()$*+,*$-.(/&00&1)2$0*,*30$4.(5&6*0$7(**(.$83)6*&1ning and a more 7 
favourable prognosis for this group of patients, achievement of remission should be the 8 
goal for both treatment and clinical trials [4]. However, achieving sustained response and 9 
remission remains a major challenge in the long-term management of patients with 10 
depression. 11 
Treatment resistance is one of the common principal indications for stimulation 12 
techniques, such as electroconvulsive therapy, vagus nerve stimulation (VNS) or, 13 
currently only in the context of research investigations, deep brain stimulation [5]. The 14 
rationale for the use of VNS as a long-term treatment in patients with chronic depression 15 
has been based on clinical findings in epilepsy patients as well as in neuroimaging 16 
findings in both epilepsy and depression patients showing alterations in medial and 17 
prefrontal limbic regions associated with neurotransmitters that have a role in 18 
anticonvulsive actions [6, 7]. Consequently, VNS was approved by the US Food and 19 
Drug Administration in 2005 for the adjunctive long-term treatment of chronic or 20 
recurrent depression for patients 18 years of age or older who are experiencing a major 21 
depressive episode and have not had an adequate response to 4 or more adequate 22 
antidepressant treatments. The approval required the manufacturer to conduct 2 23 
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additional studies, which are underway in the United States. The efficacy studies of VNS 1 
for treatment-resistant depression are summarized here. 2 
Results from previous naturalistic studies assessing the antidepressant effect of 3 
VNS after 12 months of active treatment in patients with treatment-resistant depression 4 
have suggested an improvement in primary outcome scores [8-10]. Response rates of 5 
29.8% and remission rates of 17.1% have been reported after 1 year of VNS in a 6 
naturalistic setting [8]; however, in a 10-week acute, sham-controlled, randomized trial of 7 
adjunctive VNS compared with stable medication, the Hamilton Depression Rating Scale 8 
(HRSD24) response rates were as low as 15.2% for the active group versus 10.0% for the 9 
sham group, with statistically significant improvement in depressive symptoms only for 10 
secondary outcome measures [11]. Although the 12-month outcome of a VNS-treated 11 
group has been compared with treatment as usual, efficacy and the time course for 12 
antidepressant effects remain unclear [10].  13 
We investigated symptomatic outcomes in a cohort of patients with treatment- 14 
refractory mood disorders treated with VNS over a 24-month period in this open-label, 15 
uncontrolled, European multicenter trial. Results of the first 3 months (acute phase) and 16 
the first 12 months (long-term phase) of this study have been reported [12]. Specifically, 17 
we were interested to know whether depression severity improved at 24-month follow-18 
up; whether improvements in depressive symptoms were sustained beyond the 12-month 19 
period; and whether VNS was tolerated over a 2-year period.  20 
PA T I E N TS A ND M E T H O DS 21 
Patients 22 
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Independent Ethics Committees at each study site approved the protocol, and all 1 
patients gave written informed consent before enrollment in the study. 2 
Patient eligibility requirements for the study included diagnosis of a major 3 
depressive episode (MDE) according to DSM-IV, a chronic (2 years or more) current 4 
MDE or a history of recurrent MDEs (at least 4 lifetime MDEs including the current 5 
MDE). During the current MDE, at least 2 adequate trials of antidepressant treatments 6 
measured with the Antidepressant Treatment History Form (ATHF) [13] had failed to 7 
bring about a meaningful clinical response. Additional main eligibility requirements 8 
included a trial o8$,*$9(,0*$:$;((<0$18$40=6+1*+(.,4=>$,$061.($18$?@A$1)$*+($@B-item 9 
Hamilton Rating Scale of Depression (HRSD24), and stable psychopharmacological 10 
medication for at least 4 weeks before baseline. Exclusion criteria included atypical 11 
depression, psychotic symptoms, schizophrenia, schizoaffective disorder, delusional 12 
disorder, rapid cycling bipolar disorder; secondary diagnosis of or signs of delirium, 13 
dementia, amnestic, or other cognitive disorders per DSM-IV; failure at antidepressant 14 
resistance rating (ARRC$061.($?!$18$D$1.$/1.($,)*&5(4.(00,)*$*.(,*/()*0$53.&)E$*+($15 
current depressive episode; suicide attempt requiring medical treatment within the 16 
previous 12 months, 2 or more suicide attempts during the previous 12 months, or 17 
suicidal tendencies; alcohol or substance dependence within the previous 12 months or 18 
abuse during the previous 6 months other than nicotine; participation in other 19 
investigational trials; significant cardiac or pulmonary conditions, or likelihood of 20 
requiring whole-body magnetic resonance imaging (MRI) after implantation. 21 
Study Device  22 
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Vagus Nerve Stimulation Therapy (Cyberonics, Houston, Texas) is a 1 
nonpharmacologic treatment that involves the surgical implantation of a small pulse 2 
generator subcutaneously in the left thoracic region. Electrodes attached to the left 3 
cervical vagus nerve are connected to the pulse generator by a lead, which is tunneled 4 
under the skin. After the clinician programs the device, it delivers chronic intermittent 5 
electrical stimulation to the vagus nerve.  6 
Study Design 7 
The study was designed to extend the findings of a pilot study conducted in the 8 
United States [6, 9] in an open-label, non-randomized, single-arm, longitudinal, 9 
multicenter design that evaluated the use of VNS in patients with unipolar or bipolar 10 
depression. The study was conducted at 11 study sites located in 6 European countries 11 
(Belgium, Germany, Ireland, Sweden, Switzerland, and the United Kingdom) between 12 
2000 and 2005. Further study details have been described elsewhere (12).   13 
Outcome Measures  14 
Effectiveness 15 
The primary outcome measure was improvement from baseline values over time 16 
in the scores of the 28-item Hamilton Rating Scale for Depression (HSRD28). The 17 
secondary outcome measures were changes in scores on the Montgomery-Åsberg 18 
Depression Rating Scale (MADRS), the Inventory of Depressive Symptoms-Self Report 19 
(IDS-SR30), Clinical Global Impression Scale Severity (CGI-S), and the Clinical Global 20 
Impressions Improvement (CGI-I). We report the results of testing at 3, 12, and 24 21 
months. 22 
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-F(041)0(2$;,0$5(8&)(5$a priori as a 50% or greater reduction in the HRSD28 1 
scores compared with the mean score of 2 baseline visits. For secondary outcomes, 2 
response was defined as a reduction of 50% or more in the score compared with baseline 3 
for the MADRS or the IDS-SR30#$-F(/&00&1)2$;,0$5(8&)(5$a priori ,0$,$061.($GHA$81.$*+($4 
HRSD28, G10 for the MADRS, or G14 for the IDS-SR30.  5 
 Safety 6 
Safety was assessed by reports of adverse events. 7 
!"#$"%&'(#')*+,&$('&"#-)8 
The number of concomitant psychotropic antidepressant and antipsychotic 9 
medications taken at baseline were compared with those taken after 3, 12, and 24 months 10 
of VNS. 11 
./-'(&#+,)0+-1"#-+)2#(34-&-)12 
Data listings for response and remission were analyzed to determine the number 13 
of patients who met criteria for response and/or remission at all 3 end points (3 months, 14 
12 months, and 24 months). In addition, an analysis determined the number of patients 15 
who met criteria for response or response and remission at both 12 months and 24 16 
months. 17 
Statistical Analysis 18 
Simple descriptive statistics (mean, standard deviation) were obtained for 19 
4,*&()*02$5(/1E.,4+&6$,)5$7,0(9&)($69&)&6,9$6+,.,6*(.&0*&60#$Both observed cases (OC) and 20 
last observation carried forward (LOCF) values were provided for outcomes measures. 21 
Longitudinal profiles for mean improvement, mean percent improvement from baseline, 22 
and mood medications, consisting of 3-, 12-, and 24-month follow-up visits, were 23 
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analyzed for significant temporal trends using mixed model repeated measures (MMRM) 1 
analysis of variance methodology as implemented in the SAS GLIMMIX procedure 2 
(SAS V9); normally distributed errors and a compound symmetric variance-covariance 3 
matrix were assumed. MMRM also were used in a longitudinal analysis of the binary 4 
outcomes response, remission, and CGI-I; a binomial error distribution was assumed in 5 
conjunction with the logit link function and compound symmetric variance-covariance 6 
matrix. A p-value <0.05 was considered statistically significant; p-values were not 7 
adjusted for multiplicity of comparisons. Analyses were performed on both the OC and 8 
imputed data using the LOCF approach. 9 
R ESU L TS 10 
Patients  11 
A total of 74 patients met the inclusion criteria and had the VNS generator 12 
implanted. Of these 74, 70 (94.6%) entered the long-term follow up, with 60 (81.1%) 13 
patients evaluable at 12 months, and 49 (66.2%) patients evaluable at 24 months (F igure 14 
1). One patient for whom results were not available at 12 months did have results at 24 15 
months. Of the 24 patients who exited the study before the 24-month endpoint, 8 (33.3%) 16 
patients had met the criteria for response at the end point before their exit, and 5 (20.8%) 17 
had also met the criterion for remission. Reasons for study exit included consent 18 
withdrawal, death, lack of efficacy, and adverse events. Patients were not explanted at the 19 
24-month follow up. In the 24-month analysis, long-term data for the OC sample were 20 
analyzed for HRSD28 (n = 49), MADRS (n = 49), IDS-SR30 (n = 46), and CGI-S (n = 49). 21 
For all assessments under LOCF, the sample size was 74.  22 
**Insert figure 1 about here ** 23 
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Mean age of patients was 47.4 ! 11.7 years (median 46.5; range 23.0 to 78.0). 1 
One patient, age 78 years, was older than the 75 years specified as the upper limit in the 2 
inclusion criteria. Women comprised 68% of the cohort. Most had MDD (54 patients, 3 
73%), and more than half of the patients (41 patients, 55.4%) had recurrent MDD, 13 4 
patients (17.6%) had a single major depressive episode, and 20 (27%) had bipolar 5 
disorder (9/74 bipolar I and 11/74 bipolar II). Further demographic and clinical data are 6 
summarized in Table 1.  7 
**Insert table 1 about here** 8 
Effectiveness 9 
Results for the primary and secondary efficacy measures at 3, 12, and 24 months 10 
are provided in Table 2 and F igure 2a and 2b. Table 3 compares improvement in the 11 
scores of primary and secondary efficacy measures between follow-up intervals. The 12 
improvement in the primary efficacy measure, the HRSD28 score, was statistically 13 
significant for OC and LOCF in the 3-month versus 12-month comparison (p = 0.003, 14 
OC; p = 0.018, LOCF) and 3-month versus 24-month comparison (p = 0.010, OC; p = 15 
0.016, LOCF) assessments only. In the secondary efficacy measures, comparisons of 16 
improvement in the scores were significant for the MADRS at 3 versus 24 months (p = 17 
0.013, OC; p = 0.014, LOCF); for the IDS-SR30 at 3 versus 12 months (p = 0.047, OC) 18 
and 3 versus 24 months (p = 0.025, OC; p = 0.020, LOCF); and for the CGI-S at 3 versus 19 
12 months (p = 0.024, OC) and 3 versus 24 months (p = 0.007, OC; p = 0.009, LOCF). 20 
None of the CGI-I comparisons were significant. 21 
**Insert table 2 and table 3 about here** 22 
**Insert figure 2a and 2b about here** 23 
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F igure 3 shows the percentages of patients who met the criteria for response on 1 
the HRSD28, as well as the secondary measures of the MADRS and the IDS-SR30. Table 2 
4 lists pairwise comparisons of percentages of responders for the same efficacy measures. 3 
Comparisons of percentages of responders were statistically significant for 3 versus 12 4 
months for the HRSD28 (p = 0.046, OC), 3 versus 24 months for the MADRS (p = 0.042, 5 
OC), and 3 versus 12 months for the IDS-SR (p = 0.035, OC). 6 
**Insert table 4 about here** 7 
**Insert figure 3 about here** 8 
F igure 4 shows the percentages of patients who met the criteria for remission at 9 
each time point. In the OC sample, 27.1% of the initial 70 patients were remitters after 24 10 
months. For the LOCF HRSD28 sample, the percentage of remitters increased across 11 
time: from 17.6% (13/74) to 29.7% (22/74) to 32.4% (24/74) at 3, 12, and 24 months, 12 
respectively. The IDS-SR percentage of remitters also more than doubled from 3 months 13 
to 24 months for both the OC and LOCF samples. Table 5 lists pairwise comparisons of 14 
the percentage of patients who met the requirements for remission. Differences were 15 
statistically significant for the HRSD28 at 3 months versus 12 months (p = 0.023, OC;      16 
p = 0.042, LOCF) and at 3 months versus 24 months (p = 0.013, OC; p = 0.015, LOCF). 17 
None of the comparisons were statistically significant for the MADRS. Differences were 18 
significant for the IDS-SR30 at 3 versus 12 months (p = 0.035, LOCF) and 3 versus 24 19 
months (p = 0.029, OC, p = 0.020, LOCF). 20 
**Insert table 5 about here** 21 
**Insert figure 4 about here** 22 
Concomitant Medications 23 
LONGTERM VNS IN DEPRESSION 
 
  11 
No statistically significant differences were found at 3, 12, or 24 months for the 1 
number of concomitant antidepressant drugs (p = 0.62; mean/median 3-months = 1.3/1.0; 2 
12-months = 1.3/1.0; 24-months = 1.2/1.0) or antipsychotic drugs (p = 0.90; 3 
mean/median 3-months = 1.5/1.0; 12-months = 1.3/1.0; 24-months = 1.3/1.0) (data not 4 
shown). 5 
Safety 6 
The most common adverse events reported at 3 months (acute phase) were voice 7 
alteration (24.1%), cough (10.7%), pain (20.8%), and dyspnea (5.1%) (data not shown). 8 
At 12 and 24 months (long-term phase), the most commonly reported adverse events 9 
were voice alteration (24.8%), pain (10.7%), and depression (5.6%) (data not shown). 10 
Two patients discontinued the study because of an adverse event and 2 patients were 11 
explanted, one because of aggravation of illness. Twenty-seven patients reported 39 12 
serious adverse events that resulted in hospitalization, including worsening of depression 13 
(13/39, 33.3%); infection (3/39, 7.7%); suicide attempt (2/39, 5.1%); overdose (2/39, 14 
5.1%); mixed state (1/39, 2.6%); and manic reaction (1/39, 5.1%). Two patients (2/74; 15 
2.7%), both women, died on study by suicide within the first year of treatment. One 16 
woman, age 48 years, who completed suicide had not responded to VNS and had no prior 17 
suicide attempts.  The other woman, age 40 years, who completed suicide had responded 18 
to VNS and had 18 life-time suicide attempts. Both had been diagnosed with Major 19 
Depressive Disorder, Recurrent. 20 
Sustained Response Analysis 21 
 Figure 5 shows the progression of patients who met or did not meet the criteria for 22 
response at the 3-month assessment and their response status at the 12- and 24-month 23 
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assessments. In the OC sample, of the 26 patients who met the criteria for response at the 1 
3-month assessment, 15 (58%) patients were responders at both 3 and 12 months, and 10 2 
(38%) patients were responders at 3, 12, and 24 months (Figure 5a). Also in the OC 3 
sample, of the 13 patients who met the criteria for remission at the 3-month assessment, 5 4 
(38%) patients were remitters at both 3 and 12 months, and 4 (31%) were remitters at 3, 5 
12, and 24 months (data not shown). In the LOCF sample, of the 26 patients who met the 6 
criteria for response at the 3-month assessment, 16 (62%) patients were responders at 7 
both 3 and 12 months, and 13 (50%) patients were responders at 3, 12, and 24 months 8 
(Figure 5b). Also in the LOCF sample, of the 13 patients who met the criteria for 9 
remission at the 3-month assessment, 6 (46%) patients were remitters at both 3 and 12 10 
months, and 5 (38%) were remitters at 3, 12, and 24 months (data not shown). 11 
56.!7..689)12 
The results of this study suggest an improvement in depression severity after 13 
treatment for 24 months with the addition of VNS to existing medication regimens in a 14 
population of patients with chronic treatment-refractory depression. Importantly, more 15 
than half of the patients (OC) met the criteria for response and more than one-third met 16 
the criteria for remission after 2 years of treatment with VNS. Also, the percentage of 17 
patients who met the requirements for response as well as remission increased 18 
continuously with the increasing duration of treatment. In addition, the analysis for 19 
sustained response showed that 38% of the patients who met criteria for response and 20 
31% who met criteria for remission after 3 months of VNS also met those criteria after 21 
both 12 and 24 months.  22 
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Although VNS failed to show relevant acute antidepressant effects in the only 1 
sham-controlled trial published to date [11], other noncontrolled studies [8, 12] have 2 
reported response rates between 27% and 53% after 1 year. In another study, response 3 
rates were 42% and remission rates 22% after 2 years of treatment [9]. Within the group 4 
of responders in this latter study, more than 60% had substantial and durable clinical 5 
benefit after 12 and 24 months of treatment [9].  6 
The observation that more than 50% (26/49, OC) of the patients in our study met 7 
criteria for response after 2 years of treatment suggests a sustained response to VNS for 8 
many patients. Comparisons with other antidepressant interventions are difficult because 9 
long-term data rarely are available, particularly in a population of patients with treatment-10 
resistant depression. It is noteworthy; that our overall responses are better compared to 11 
previously reported VNS Therapy US long term follow studies. 12 
In theory, at least, 4 factors may account for the relatively high percentage of 13 
responders seen after 2 years of treatment in our study: effects of VNS, placebo effects, 14 
natural course, and concomitant medication. Usually, placebo response is characterized 15 
with a certain response pattern with stronger effects in patients with less severe and short 16 
depressive episodes as well as an early onset and nonpersistent response [14-16]. This 17 
explanation is unlikely owing to the demographics of the patients and timing of response. 18 
The influence of the natural course and concomitant medication cannot be ruled out, 19 
although participation in a study may have certain antidepressant effects. However, in a 20 
study investigating the course of patients treated with VNS and patients treated with 21 
therapy as usual in a comparable sample, VNS was associated with a more profound 22 
antidepressant effect after 12 months [10].  23 
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The second finding of an increasing percentage of patients who met remission 1 
criteria over time, is of interest. Compared with nonresponse and response, remission 2 
(referred to as the absence clinically significant depressive symptoms [4]) has been linked 3 
to a lower likelihood of relapse and recurrence [17], a better level of functioning [18], a 4 
better prognosis [19], and a more stable course [20]. Although treatment resistance is a 5 
factor that negatively influences time to and likelihood of achieving remission [1,13], our 6 
data indicate that chronic VNS may be capable of achieving long-term clinical remission 7 
in some patients.  8 
With regard to maintenance of response, 10 of the patients followed in this study 9 
(OC analysis) were responders at all 3 follow-up intervals, 3, 12, and 24 months. Of 17 10 
patients whose response was first recorded at 12 months, 9 were also responders at 24 11 
months. Four patients who responded at 3 months but did not meet response criteria at 12 12 
months regained response at 24 months. Four patients met remission criteria at all follow-13 
up intervals. In comparison, a follow-up study of 347 patients who received ECT in 14 
community settings reported remission rates of 30.3% to 46.7% (depending on criteria) 15 
and a relapse rate of 64.3% during 24 weeks of follow-up [21]. Comparisons with reports 16 
of sustained response with antidepressant medications are complicated by issues with 17 
adherence, differences in the degree of treatment resistance, and study duration. Follow-18 
up during the Sequenced Treatment Alternatives to Relieve Depression (STAR-D) study 19 
showed that the relapse rate of patients who achieved remission increased and the time to 20 
relapse decreased as the number of treatment steps increased (Step 1: 33.5%, 4.4 months; 21 
Step 2: 47.4%, 4.5 months; Step 3: 42.9%, 3.9 months; Step 4: 50.0%, 2.5 months) [3]. 22 
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Considering the severity and duration of the depressive illness among these patients 1 
receiving VNS, their rates of sustained response and remission are impressive. 2 
An additional finding is that adverse effects notably weakened with increasing 3 
treatment duration. Albeit previously described in long-term studies in patients treated 4 
with antidepressant or anticonvulsant VNS, the good tolerability of VNS may have led to 5 
relatively good adherence rates: 66% of the initially included patients received VNS after 6 
the 24-month study ended. In this context, it is of importance that nonadherence remains 7 
one of the most common problems in the treatment of patients with depression. 8 
Nonadherence rates of up to 60% in depressive patients who were receiving 9 
psychopharmacological medication have been reported [22]. Beside lack of patient 10 
information and a poor quality of patient-physician relationship, the main reasons for 11 
discontinuing antidepressant therapy are unpleasant side effects and a complex intake 12 
regimen [23]. VNS has the advantage of being able to deliver sustained and active 13 
treatment independently of the factors normally associated with non-adherence to 14 
medication regimes. 15 
The two suicides within the 24 months indicate a suicide prevalence rate of 3% 16 
which is above the range one would expect in patients with treatment-resistant depression 17 
[24].  18 
Two suicides occurred during the first year of this study. Comparing the suicide 19 
prevalence rate with that of other antidepressive treatments is difficult because few 20 
studies report outcomes of patients with the degree of treatment resistance of the patients 21 
in the present study. Khan et al [25] studied suicide rates of patients who received 22 
selective serotonin reuptake inhibitors (SSRIs) or other antidepressants in FDA trials of 23 
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investigational antidepressants. These patients were described as having mild to moderate 1 
depression, and not being actively suicidal at the beginning of the trial. For patients 2 
receiving SSRIs, the suicide rate by patient exposure years was 0.59% (95% CI 0.31-3 
0.87), 17 suicides in 2,864 exposure years, and for those receiving other antidepressants, 4 
it was 0.76% (CI 0.49-1.03), 31 suicides in 4,094 exposure years [25]. In the present 5 
study of patients with chronic or recurrent, treatment-refractory depression, the suicide 6 
rate by patient exposure years was 1.57%, 2 suicides in 127 exposure years. This 7 
percentage was derived by dividing the number of suicides (n=2) by the exposure, the 8 
cumulative number of months (converted to years) that patients received VNS. The 9 
exposure years were calculated from implantation to the last assessment date before exit.!10 
The rate in the present study of patients with treatment-resistant depression is 1.57%, 11 
;+&6+$&0$,713*$+,98$,E,&)$,0$/36+$,0$*+($344(.$61)8&5()6($&)*(.',9$IH#A!JC$18$*+($K1*+(.$12 
,)*&5(4.(00,)*L$E.134>$;+1$;(.($6+,.,6*(.&M(5$,0$/&959=$*1$/oderately depressed.!13 
This study presents both means with standard deviations and medians with ranges 14 
and interquartile ranges as well as both LOCF and OC outcomes. Given the skewed 15 
nature of these data, medians with ranges and interquartile ranges are more appropriate to 16 
describe central tendencies. However, a decision to report only medians with ranges and 17 
interquartile ranges in the present study, without also including means and standard 18 
deviations, would certainly frustrate any efforts for direct comparisons with the previous 19 
VNS studies, which presented means and standard deviations. The same reasoning, to 20 
allow for comparison and continuity, applies to the reporting of both LOCF and OC 21 
results. Previously published VNS analyses presented both OC and LOCF results and 22 
allowed readers to draw their own conclusions. A similar opportunity is accorded here. 23 
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The OC approach may overestimate the effect of an intervention because it does 1 
not account for the outcomes of study participants whose outcomes are unknown, (eg, 2 
lost to follow-up or withdrawn from the study). The LOCF approach, which involves 3 
imputation of values by carrying forward outcomes of patients no longer active in the 4 
study, may also have limitations associated with the reasons that study participants were 5 
lost to follow-up or withdrew. The MMRM predicts data for patients lost to follow-up by 6 
drawing on the actual patient data before dropout. Prakash et al [26] used data from an 8-7 
month outpatient depression trial to compare analyses using LOCF, MMRM, and OC. 8 
They found that within-group mean changes were consistently underestimated with 9 
LOCF and overestimated by OC when they were compared with the more robust MMRM 10 
[26]. In simulation studies, Siddiqui et al [27] found inflated Type I error rates and 11 
substantial bias in estimated treatment effects with LOCF analysis. They characterized 12 
MMRM analysis 3)5(.$*+($&E)1.,79($/&00&)E$5,*,$8.,/(;1.<$,0$,$K0()0&79($,),9=*&6$13 
6+1&6(L$81.$(88&6,6=$(',93,*&1)$7(6,30($&*$0((/(5$.1730*$*1$(0*&/,*($*.3($*.(,*/()*$14 
differences and control the number of Type I errors [27]. 15 
The encouraging data in this study must, however, be interpreted with appropriate 16 
caution in the light of two major design limitations. First, the lack of a control group 17 
makes it difficult to compare the clinical outcome with those of other 18 
psychopharmacological, psychotherapeutic, or brain stimulation interventions, and to 19 
disentangle the effects of VNS from the non-specific effects of study participation. This 20 
shortcoming has, to an extent,  been considered in a previous study in which patients who 21 
received long-term treatment with VNS were matched with comparably ill patients who 22 
were receiving treatment as usual [10]. In this study, the authors described one-year 23 
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response rates that were comparable to the results of our study and, more interestingly, a 1 
superiority of VNS treatment compared with standard treatment. 2 
The second major limitation of the present study is that neither stimulation 3 
parameters nor further antidepressant treatments were controlled, although the differences 4 
in the overall numbers of antidepressant and other psychotropic treatments did not differ 5 
significantly. Hence, it is important that future studies should control for these parameters 6 
and include a control group.  7 
In summary, these data suggest that long-term VNS treatment in addition to 8 
medication can offer the possibility of meaningful and sustained clinical benefit for 9 
patients who have not achieved satisfactory response with conventional treatment. 10 
Additionally, VNS appears to have a comparatively benign adverse effect profile, and 11 
favorable adherence rates in a relevant proportion of patients with treatment-resistant 12 
depression. Future studies should closely evaluate possible changes in suicidality 13 
associated with VNS.  14 
15 
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Table 1: Baseline Demographic and Clinical Data (n=74)  1 
Characteristic Value 
Age at implant (years) (mean ± SD) 
Median (IQ) range 
 
 
47.4 + 11.7 
46.5 (17.0)  23.0, 78.0 
 
 
 
Women:Men (%)  2.1:1 (67.6% women) 
White (%) 98.65 
MDD, recurrent (%) 55.41 
MDD, single episode (%) 17.57 
Bipolar disorder (%)a  27.0 
Length of current MDE (years) (mean ± SD) 
Median (IQ) range 
 
3.5 + 6.3 
2.0 (2.9)  0.1, 46.7 
Total duration of MDD (years) (mean ± SD) 
Median (IQ) range 
 
19.1 + 10.5 
17.5 (16.0)  3.0, 50.0 
Age of onset of first MDE (years) (mean ± SD) 28.8 + 12.0 
Suicide attempts in lifetime (n) (mean ± SD) 1.1 + 2.3 
ECT in lifetime (n=37) (%)  50.0 
ECT in current MDE (n=27) (%) 36.5 
Baseline HRSD28 score (mean ±SD) Lower, Upper 95% CI 
Median (IQ) range 
 
 
 
 
 
 
 
 
 
 
34.0 + 5.8; 32.7, 35.4 
34.0 (7.5)  23.5, 50.5 
Baseline MADRS score (mean ±SD) Lower, Upper 95% CI 
Median (IQ) range 
 
 
 
 
 
 
 
 
 
32.9 + 6.4; 31.4, 34.4 
32.5 (9.0)  17.5, 46.0 
Baseline IDS-SR30 score (mean ±SD) Lower, Upper 95% CI 
Median (IQ) range 
 
47.6 + 9.1; 45.4, 49.8 
48.0 (11.0)  27.0, 74.0 
Baseline CGI Severity of Illness Score (mean ±SD) Lower, Upper 95% CI 
Median (IQ) range 
 
5.5 + 0.9; 5.3, 5.7 
6.0 (1.0)  3.0, 7.0 
Unsuccessful ATHF-defined treatments in current MDE  
(mean ±SD) Median (IQ) range 
 
 
 
3.5 + 1.3 
3.0 (2.0)  2.0 7.0 
a. Bipolar I, n = 9; bipolar II, n = 11 2 
ATHF = Antidepressant Treatment History Form; CGI = Clinical Global Impression scale, Global 3 
Assessment of Functioning; ECT = electroconvulsive therapy; HRSD28 = Hamilton Rating Scale for 4 
Depression; IDS-SR30 = Inventory of Depressive Symptoms- Self Report; MADRS = Montgomery Åsberg 5 
Depression Scale; MDD = major depressive disorder; MDE = major depressive episode 6 
7 
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Table 2: Outcome Measures at Baseline, 3-, 12-, and 24-month Follow-up a 1 
Outcome 
Measure 
Baseline 3 Months 12 Months 24 Months 
N Score N Score N Score N Score 
H RSD:; 
  O C 
  L O C F 
 
74 
74 
 
34.0 ± 5.8 
34.0 ± 5.8 
 
70 
74 
 
22.1 ± 11.5b 
22.8 ± 11.9 b 
 
60 
74 
 
16.4 ± 10.4 b 
19.5 ± 12.4 b 
 
49 
74 
 
17.0 ± 11.9 b 
19.5 ± 12.9 b 
M A DRS 
  O C 
  L O C F 
 
74 
74 
 
32.9 ± 6.4 
32.9 ± 6.4 
 
70 
74 
 
20.5 ± 11.7 b 
21.1 ± 11.7 b 
 
57 
74 
 
16.2 ± 11.8 b 
19.2 ± 12.6 b 
 
49 
74 
 
15.3 ± 12.1 b 
17.6 ± 12.6 b 
IDS-SR<=)
  O C 
  L O C F 
 
71 
71 
 
47.6 ± 9.1 
47.6 ± 9.1 
 
68 
74 
 
33.2 ± 15.9 b 
34.2 ± 15.7 b 
 
58 
74 
 
27.8 ± 16.9 b 
31.0 ± 17.5 b 
 
46 
74 
 
26.4 ± 17.8 b 
29.6 ± 17.7 b 
C G I-S 
O C 
L O C F 
 
74 
74 
 
5.5 ± 0.9 
5.5 ± 0.9 
 
70 
74 
 
3.9 ± 1.6 
4.0 ± 1.6 
 
60 
74 
 
3.3 ± 1.6 
3.7 ± 1.7 
 
49 
74 
 
3.2 ± 1.8 
3.5 ± 1.8 
a. All scores reported as mean ± SD; b. statistical9=$0&E)&8&6,)*$8.1/$7,0(9&)($4GA#AV 2 
CGI = Clinical global Impression scale, Global Assessment of Functioning; HRSD28 = 28-Item 3 
Hamilton Rating Scale for Depression; IDS-SR30 = Inventory of Depressive Symptoms- Self 4 
Report; LOCF = last observation carried forward, MADRS = Montgomery Åsberg Depression 5 
Scale; OC = observed cases 6 
7 
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Table 3: Pairwise Comparisons: Improvement  1 
in Score from Baseline 2 
H RSD:; Comparison Lower 95% C I Upper 95% C I p-value 
O C 
3 month vs 12 month 1.81 8.41 0.003* 
3 month vs 24 month 1.12 8.19 0.010* 
12 month vs 24 month -4.08 3.16 0.802 
L O C F 
3 month vs 12 month 0.57 6.04 0.018* 
3 month vs 24 month 0.62 6.10 0.016* 
12 month vs 24 month -2.64 2.79 0.969 
M A DRS Comparison   p-value 
O C 
3 month vs 12 month -0.12 6.92 0.058 
3 month vs 24 month 1.00 8.40 0.013* 
12 month vs 24 month -2.53 5.13 0.503 
L O C F 
3 month vs 12 month -0.91 4.61 0.188 
3 month vs 24 month 0.72 6.24 0.014* 
12 month vs 24 month -1.13 4.40 0.244 
IDS-SR<=) Comparison   p-value 
O C 
3 month vs 12 month 0.06 9.52 0.047* 
3 month vs 24 month 0.74 11.00 0.025* 
12 month vs 24 month -4.16 6.33 0.682 
L O C F 
3 month vs 12 month -0.33 7.20 0.073 
3 month vs 24 month 0.73 8.26 0.020* 
12 month vs 24 month -2.70 4.82 0.580 
C G I-S Comparison   p-value 
O C 
3 month vs 12 month 0.07 0.99 0.024* 
3 month vs 24 month 0.19 1.18 0.007* 
12 month vs 24 month -0.35 0.66 0.537 
L O C F 
3 month vs 12 month -0.04 0.72 0.083 
3 month vs 24 month 0.13 0.90 0.009* 
12 month vs 24 month -0.21 0.56 0.365 
C G I-I Comparison   p-value 
O C 
3 month vs 12 month -0.66 0.23 0.338 
3 month vs 24 month -0.46 0.49 0.944 
12 month vs 24 month -0.25 0.72 0.347 
L O C F 
3 month vs 12 month -0.52 0.22 0.425 
3 month vs 24 month -0.38 0.35 0.942 
12 month vs 24 month -0.23 0.50 0.468 
* = statistically 0&E)&8&6,)*$5&88(.()6($I4$G$A#AVC 3 
CGI-I = Clinical Global Impression-Improvement, CGI-S= 4 
Clinical Global Impression-Symptomology , HRSD28 = 28-Item 5 
Hamilton Rating Scale for Depression; IDS-SR30 = Inventory of 6 
Depressive Symptoms- Self Report; LOCF = last observation 7 
carried forward, MADRS = Montgomery Åsberg Depression 8 
Scale; OC = observed cases 9 
10 
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Table 4: Pairwise Comparisons: Percent Responders  1 
H RSD:; Comparison Lower 95% C I Upper 95% C I p-value 
O C 
3 month vs 12 month 0.01 1.26 0.046* 
3 month vs 24 month -0.05 1.28 0.071 
12 month vs 24 month -0.69 0.65 0.949 
L O C F 
3 month vs 12 month -0.13 0.92 0.136 
3 month vs 24 month -0.07 0.97 0.090 
12 month vs 24 month -0.46 0.57 0.833 
M A DRS Comparison   p-value 
O C 
3 month vs 12 month -0.09 1.13 0.096 
3 month vs 24 month 0.02 1.32 0.042* 
12 month vs 24 month -0.51 0.82 0.652 
L O C F 
3 month vs 12 month -023 0.79 0.278 
3 month vs 24 month -0.06 0.95 0.086 
12 month vs 24 month -0.34 0.66 0.520 
IDS-SR<=) Comparison   p-value 
O C 
3 month vs 12 month 0.05 1.40 0.035* 
3 month vs 24 month -0.05 1.40 0.068 
12 month vs 24 month -0.77 0.67 0.888 
L O C F 
3 month vs 12 month -0.01 1.15 0.056 
3 month vs 24 month -0.01 1.15 0.056 
12 month vs 24 month -0.55 0.55 1.000 
* = statistically significant difference I4$G$A#AVC 2 
 3 
F(041)0($;,0$?VAJ$.(536*&1)$8.1/$7,0(9&)($,00(00/()*$061.( 4 
 5 
Abbreviations: HRSD28 = 28-Item Hamilton Rating Scale for 6 
Depression; IDS-SR30 = Inventory of Depressive Symptoms- 7 
Self Report; LOCF = last observation carried forward, MADRS 8 
= Montgomery Åsberg Depression Scale; OC = observed cases 9 
10 
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Table 5: Pairwise Comparisons: Percent Remitters  1 
H RSD:; Comparison Lower 95% C I Upper 95% C I p-value 
O C 
3 month vs 12 month 0.12 1.60 0.023* 
3 month vs 24 month 0.21 1.76 0.013* 
12 month vs 24 month -0.60 0.85 0.721 
L O C F 
3 month vs 12 month 0.03 1.35 0.042* 
3 month vs 24 month 0.16 1.47 0.015* 
12 month vs 24 month -0.46 0.72 0.672 
M A DRS Comparison   p-value 
O C 
3 month vs 12 month -0.39 1.03 0.375 
3 month vs 24 month -0.31 1.18 0.250 
12 month vs 24 month -0.64 0.87 0.768 
L O C F 
3 month vs 12 month -0.49 0.77 0.668 
3 month vs 24 month -0.29 0.95 0.294 
12 month vs 24 month -0.42 0.80 0.533 
IDS-SR<=) Comparison   p-value 
O C 
3 month vs 12 month -0.05 1.78 0.063 
3 month vs 24 month 0.11 2.02 0.029* 
12 month vs 24 month -0.66 1.06 0.642 
L O C F 
3 month vs 12 month 0.06 1.69 0.035* 
3 month vs 24 month 0.15 1.77 0.020* 
12 month vs 24 month -0.60 0.77 0.807 
W$X$0*,*&0*&6,99=$0&E)&8&6,)*$5&88(.()6($I4$G$A#AVC 2 
 3 
F(/&00&1)T$GHA$YFZ[28>$GHA$PU[FZ>$GHB$\[Z-SR30 4 
 5 
Abbreviations: HRSD28 = 28-Item Hamilton Rating Scale for Depression; IDS-SR30 = Inventory 6 
of Depressive Symptoms- Self Report; LOCF = last observation carried forward, MADRS = 7 
Montgomery Åsberg Depression Scale; OC = observed cases8 
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F igure 1: Patient Disposition 1 
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 30 
F igure 2: Least Squares Means. Panel A = Percent Improvement F rom Baseline for 1 
H RSD:;, M A DRS, and IDS-SR<=. Panel B = Improvement F rom Baseline for C G I-S 2 
and C G I-I . L O C F = last observation car ried forward; O C = observed cases  3 
 4 
Abbreviations: CGI-I = Clinical Global Impression-Improvement, 5 
CGI-S= Clinical Global Impression-Symptomology , HRSD28 = 28-6 
Item Hamilton Rating Scale for Depression; IDS-SR30 = Inventory 7 
of Depressive Symptoms- Self Report; LOCF = last observation 8 
carried forward, MADRS = Montgomery Åsberg Depression Scale; 9 
OC = observed cases 10 
11 
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>&?/@+)<A)0+-1"#,+@-).(%13+)B+@$+#'(?+-A)C0.5:;D)*250.D)(#,)65.E.0<=F)1 
)2 
Abbreviations: HRSD28 = 28-Item Hamilton Rating Scale for Depression; IDS-SR30 = Inventory 3 
of Depressive Symptoms- Self Report; LOCF = last observation carried forward, MADRS = 4 
Montgomery Åsberg Depression Scale; OC = observed cases)5 
 6 
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>&?/@+)GA)0+%&''+@-).(%13+)B+@$+#'(?+-A)C0.5:;D)*250.D)(#,)65.E.0<=F)1 
 2 
Abbreviations: HRSD28 = 28-Item Hamilton Rating Scale for Depression; IDS-SR30 = Inventory 3 
of Depressive Symptoms- Self Report; LOCF = last observation carried forward, MADRS = 4 
Montgomery Åsberg Depression Scale; OC = observed cases)5 
6 
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F igure 5: Sustained Response Analysis. Panel A = Observed Cases. Panel B = Last 1 
Observation Carried Forward 2 
 3 
F(041)0($;,0$?VAJ$.(536*&1)$8.1/$7,0(9&)($,00(00/()*$061.($&)$*+($YFZ[28. 4 
 5 
Abbreviation: HRSD28 = 28-Item Hamilton Rating Scale for Depression 6 
F
ig
u
re
s
C
li
c
k
 h
e
re
 t
o
 d
o
w
n
lo
a
d
 h
ig
h
 r
e
s
o
lu
ti
o
n
 i
m
a
g
e
F
ig
u
re
s
C
li
c
k
 h
e
re
 t
o
 d
o
w
n
lo
a
d
 h
ig
h
 r
e
s
o
lu
ti
o
n
 i
m
a
g
e
F
ig
u
re
s
C
li
c
k
 h
e
re
 t
o
 d
o
w
n
lo
a
d
 h
ig
h
 r
e
s
o
lu
ti
o
n
 i
m
a
g
e
F
ig
u
re
s
C
li
c
k
 h
e
re
 t
o
 d
o
w
n
lo
a
d
 h
ig
h
 r
e
s
o
lu
ti
o
n
 i
m
a
g
e
F
ig
u
re
s
C
li
c
k
 h
e
re
 t
o
 d
o
w
n
lo
a
d
 h
ig
h
 r
e
s
o
lu
ti
o
n
 i
m
a
g
e
F
ig
u
re
s
C
li
c
k
 h
e
re
 t
o
 d
o
w
n
lo
a
d
 h
ig
h
 r
e
s
o
lu
ti
o
n
 i
m
a
g
e
F
ig
u
re
s
C
li
c
k
 h
e
re
 t
o
 d
o
w
n
lo
a
d
 h
ig
h
 r
e
s
o
lu
ti
o
n
 i
m
a
g
e
LONGTERM VNS IN DEPRESSION 
A C K N O W L E D G E M E N TS A ND F IN A N C I A L DISC L OSUR E 
Under the direction of the authors, John C. Allen, Jr., PhD, and Amara K. 
Jayewardene, MS, performed the statistical analysis for this report. Dr. Allen and Mr. 
Jayewardene were employees of Cyberonics, Inc., manufacturer of the VNS Therapy System, 
and Dr. Allen owns Cyberonics stock. Malek Bajbouj MD and Angela Merkl MD 
independently confirmed this analysis. Penny Clowe, RN, MA, MaryAnn Foote, PhD, and 
Susan E. Siefert, ELS, CBC, assisted with medical writing services during the development of 
this manuscript. Ms Clowe and Ms Siefert were employees of Cyberonics, and Ms Siefert 
owns Cyberonics stock. Dr. Foote was compensated by Cyberonics.  
 
*Author Disclosures
!"#$%&#'('%)*%+"'%$,-.#$$#)/%#$%-'#/0%$'/+%1#2%.2#34
*Copyright Release Form
